Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | PDE4A | P27815 | 3/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11628763 | 0.78 | KMT2A (0.64) | LMNAMEN1KMT2ACYP1A2PDE4A | |
| SCHEMBL11035831 | 0.77 | LMNA (1.00) | LMNAMEN1KMT2ACYP1A2PDE4A | |
| SCHEMBL11245554 | 0.74 | PRMT5 (0.47) | LMNACYP1A2PDE3BPDE3AMAPT | |
| SCHEMBL23815328 | 0.74 | CYP2A6 (0.43) | PRMT5WDR77CYP11B2ALKCYP11B1 | |
| SCHEMBL11156334 | 0.74 | CYP1A2 (0.67) | LMNAMEN1KMT2ACYP1A2PDE4A | |
| SCHEMBL11235123 | 0.74 | LMNA (0.62) | LMNAMEN1KMT2ACYP1A2PDE4A | |
| SCHEMBL3452908 | 0.73 | LMNA (0.80) | LMNAMEN1KMT2ACYP1A2PDE4A | |
| SCHEMBL4052280 | 0.72 | LMNA (0.66) | LMNAMEN1KMT2ACYP1A2PDE4A | |
| SCHEMBL12595727 | 0.72 | LMNA (0.66) | LMNAMEN1KMT2ACYP1A2PDE4A | |
| SCHEMBL14910773 | 0.72 | CYP11B2 (0.42) | MEN1KMT2ACYP1A2PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511038-B2 | Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-31 | — | — | US | disclosed |
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-23 | — | — | US | disclosed |
| CN-1878759-A | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | ALMIRALL PRODESFARMA SA (ES) | 2006-12-13 | — | — | CN | disclosed |
| EP-1682519-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049581-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-06-02 | — | — | WO | disclosed |
| US-4346221-A | Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones | STERLING DRUG INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4338446-A | Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates | STERLING DRUG INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4305943-A | 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics | STERLING DRUG INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4304776-A | 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics | STERLING DRUG INC. (US) | 1981-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE7A | LMNA 4446/4885MEN1 4864/4885KMT2A 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.